文献速递冠心病心力衰竭与心肌病

缺血性心肌病心衰患者CABG术后十年结局的年龄差异:STICH试验扩展随访分析

Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction: An Analysis of the Extended Follow-Up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure).
PubMed 文献 · Circulation · 2016-08-29

基于STICH试验1212例射血分数≤35%且适合CABG的冠心病心衰患者,中位随访9.8年,按年龄四分位分组分析。结果显示CABG对全因死亡及全因死亡联合心血管住院的获益在年轻患者中更显著,但对心血管死亡的获益在各年龄段一致。

要点

  • CABG对全因死亡的获益随年龄增长呈减弱趋势(交互P=0.062)。
  • CABG对心血管死亡的获益在各年龄组间一致(交互P=0.307)。
  • 年轻患者中CABG降低全因死亡或心血管住院的幅度大于年长患者(交互P=0.004)。

核心结论

  • 在缺血性心肌病心衰患者中,CABG对全因死亡及全因死亡联合心血管住院的获益在年轻患者中更显著,但对心血管死亡的获益不因年龄而异。

研究设计与样本

  • STICH试验扩展随访分析,共纳入1212例射血分数≤35%且冠状动脉病变适合CABG的患者,随机分为CABG组或药物治疗组,中位随访9.8年。
  • 患者按年龄四分位分组:Q1≤54岁,Q2>54且≤60岁,Q3>60且≤67岁,Q4>67岁。

主要发现

  • 药物治疗组全因死亡率Q4为79%、Q1为60%(log-rank P=0.005);CABG组Q4为68%、Q1为48%(log-rank P<0.001)。
  • 心血管死亡率在药物治疗组各年龄间无统计学差异(Q4 53% vs Q1 49%,log-rank P=0.388),CABG组亦无差异(Q4 39% vs Q1 35%,log-rank P=0.103)。
  • 心血管死亡占总死亡比例在 youngest 四分位为79%,oldest 四分位为62%。
  • CABG对比药物治疗对全因死亡的影响随年龄增长趋于减弱(交互P=0.062),对心血管死亡的影响各年龄一致(交互P=0.307)。
  • CABG对比药物治疗减少全因死亡或心血管住院的获益在年轻患者中大于年长患者(交互P=0.004)。

临床怎么用

  • 对年轻缺血性心肌病心衰患者,CABG联合药物治疗可更显著降低全因死亡及全因死亡联合心血管住院风险。
  • 对年长患者,CABG对心血管死亡的获益仍一致,决策时应综合评估合并症与个体风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Advancing age is associated with a greater prevalence of coronary artery disease in heart failure with reduced ejection fraction and with a higher risk of complications after coronary artery bypass grafting (CABG). Whether the efficacy of CABG compared with medical therapy (MED) in patients with heart failure caused by ischemic cardiomyopathy is the same in patients of different ages is unknown. METHODS: A total of 1212 patients (median follow-up, 9.8 years) with ejection fraction ≤35% and coronary disease amenable to CABG were randomized to CABG or MED in the STICH trial (Surgical Treatment for Ischemic Heart Failure). RESULTS: Mean age at trial entry was 60 years; 12% were women; 36% were nonwhite; and the baseline ejection fraction was 28%. For the present analyses, patients were categorized by age quartiles: quartile 1, ≤54 years; quartile, 2 >54 and ≤60 years; quartile 3, >60 and ≤67 years; and quartile 4, >67 years. Older versus younger patients had more comorbidities. All-cause mortality was higher in older compared with younger patients assigned to MED (79% versus 60% for quartiles 4 and 1, respectively; log-rank P=0.005) and CABG (68% versus 48% for quartiles 4 and 1, respectively; log-rank P<0.001). In contrast, cardiovascular mortality was not statistically significantly different across the spectrum of age in the MED group (53% versus 49% for quartiles 4 and 1, respectively; log-rank P=0.388) or CABG group (39% versus 35% for quartiles 4 and 1, respectively; log-rank P=0.103). Cardiovascular deaths accounted for a greater proportion of deaths in the youngest versus oldest quartile (79% versus 62%). The effect of CABG versus MED on all-cause mortality tended to diminish with increasing age (Pinteraction=0.062), whereas the benefit of CABG on cardiovascular mortality was consistent over all ages (Pinteraction=0.307). There was a greater reduction in all-cause mortality or cardiovascular hospitalization with CABG versus MED in younger compared with older patients (Pinteraction=0.004). In the CABG group, cardiopulmonary bypass time or days in intensive care did not differ for older versus younger patients. CONCLUSIONS: CABG added to MED has a more substantial benefit on all-cause mortality and the combination of all-cause mortality and cardiovascular hospitalization in younger compared with older patients. CABG added to MED has a consistent beneficial effect on cardiovascular mortality regardless of age. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00023595.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Petrie MC, Jhund PS, She L, et al. Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction: An Analysis of the Extended Follow-Up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure). Circulation. 2016. PMID: 27573034. doi:10.1161/CIRCULATIONAHA.116.024800

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。